UPC_APP_43786/2024

TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIA PATIENTS BY AN INHIBITOR OF COMPLEMENT

Prozessuale & UnteranträgeKostenfestsetzungenHamburg LDGenericWritten Phase

Übersicht Entscheidungen Dokumente Zeitverlauf

Parteien

Kläger

Samsung Bioepis NL B.V.

Vertreter: Elena Hennecke (Freshfields PartG mbB)

Beklagte

Alexion Pharmaceuticals, Inc.(AstraZeneca Group)

Vertreter: Andrea Ritter (Simmons & Simmons LLP)

Richter

Sabine Klepsch
Alima Zana
Stefan Schilling
Rudi Goedeweeck

Patente

EP3167888
EP 3167888

CPC-Codes: A61P31/04, A61P25/18, A61P29/02, A61K39/395, A61K2039/505, A61P7/02, A61P25/26, A61P13/02, A61P15/10, A61P17/00, A61P7/00, A61P25/28…

Sektor: Organic Chemistry

Ausgang

Nur Kosten

Eingereicht: 26. Juli 2024

Erste Entscheidung: 1. Aug. 2025

Sprache: English

Hamburg Local Division (1 August 2025) issued a costs decision following the dismissal of Alexion Pharmaceuticals' provisional measures application against Samsung Bioepis. The court assessed Samsung Bioepis' recoverable litigation costs, disallowing the costs of two UK solicitors as disproportionate but allowing the costs of the private expert Prof. Kontermann and reasonable travel expenses.

Im UPC-Register öffnen